Skip to content
    UTHR
    Earnings call· Jun 2026(Q2 FY26)

    UNITED THERAPEUTICS Q2 FY26 earnings call UTHR

    Aug 5, 2026 Source

    Executive summary

    United Therapeutics Q2 FY26 — Strong Pipeline Progress Despite Commercial Headwinds

    United Therapeutics reported a quarter marked by significant pipeline advancements, including key regulatory submissions for ralinepag in PAH and nebulized Tyvaso in IPF, alongside progress in its organ pipeline. Despite these scientific successes, commercial performance for existing products, particularly nebulized Tyvaso, faced competitive pressures, resulting in Q2 revenue below expectations. The company is focused on accelerating performance in the second half of 2026 through an expanded sales force, while emphasizing the multi-billion dollar potential of its upcoming launches to drive future growth.

    Highlights

    6

    • Exceptional clinical results from the ADVANCE OUTCOMES study for ralinepag, demonstrating its potential as a major new oral therapy for PAH.

    • TETON 1 results for nebulized Tyvaso in IPF surpassed TETON 2, leading to an sNDA submission to the FDA.

    • Submitted two important new drug applications to the FDA: sNDA for nebulized Tyvaso in IPF and NDA for ralinepag in PAH.

    • Organ pipeline continues strong progress with UKidney EXPAND study and planned initiation of SIMO kidney extend study.

    • Acquired Thymmune Therapeutics, adding a promising thymus-based regenerative medicine platform.

    • Sales force roughly doubled and deployed by early July, increasing engagement with physicians.

    Concerns

    3

    • Total revenue for Q2 FY26 was $783 million, essentially flat with Q1, and below expectations.

    • Nebulized Tyvaso faced pressure from competitive dynamics within the inhaled prostacyclin category.

    • The path to achieve a previously projected $4 billion revenue run rate by the end of 2027 with the existing commercial portfolio has "narrowed".

    Guidance & targets

    5
    CategoryTargetConfidence
    Nebulized Tyvaso approval
    Potential approval
    high materiality
    High
    Ralinepag approval
    Potential approval
    high materiality
    High
    SMI device approval
    Potential approval
    medium materiality
    High
    TETON PPF Phase III readout
    Readout
    high materiality
    High
    Revenue run rate
    $4 billion
    high materiality
    Medium

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Total Company
    Total revenue for the second quarter of 2026 was essentially flat with the first quarter and below expectations.
    		$783M—flat—
    Tyvaso (Total)
    Total revenue for Tyvaso products.
    		$453M———
    Tyvaso DPI
    Continued to demonstrate growth and exited the quarter with significant underlying momentum, with key metrics reaching record levels.
    Starts: record levelsReferrals: record levelsTotal patients: record levelsCommercial patients: record levels
    		————

    Operational metrics

    3
    Operating efficiency
    near the top
    Q2 FY26

    Supported by a disciplined approach to capital allocation through the budget algorithm.

    Sales force size
    doubled
    Q2 FY26

    Significantly expanded to support both IPF and ralinepag indications, accelerating the process to get reps in the field by July 1.

    DPF construction
    2
    FY26

    Two additional commercial scale DPF facilities are under construction and expected to be completed by year-end.

    Industry KPIs

    6
    MetricValueDetails
    Pipeline read out calendarH2 2027
    Product franchise net sales$453MUSD
    Regulatory approvals filings2 submissions
    Peak long term sales guidance$4 billionUSD
    Prescription volume new startsrecord levels
    Clinical trial efficacy safety dataExceptional clinical results

    Deals & partnerships

    1
    Thymmune TherapeuticsAcquisition of a promising Thymus-based regenerative medicine platform.

    Acquired Thymmune Therapeutics, adding a promising Thymus-based regenerative medicine platform that fits squarely within the company's mission to restore immune function for patients with serious diseases.

    Risks & headwinds

    3
    Competitive dynamics for nebulized TyvasoQ2 FY26

    Pressured

    Mitigation: Expanded sales force, focus on differentiated therapies, accelerating adoption.

    Failure to meet revenue expectationsQ2 FY26

    Q2 revenue below expectations

    Mitigation: Focus on improving results, underlying fundamentals are strong, positioned for improved performance in H2 FY26.

    Narrowed path to $4 billion revenue run rateEnd of 2027

    Path has certainly narrowed

    Mitigation: Factoring in revenue from anticipated IPF and ralinepag launches next year to achieve and exceed the target.

    What to watch in Q3 FY26

    5

    H2 FY26 Revenue Acceleration

    H2 FY26
    CurrentQ2 FY26 revenue flat QoQ, below expectations
    TargetStronger than H1 FY26

    Why it matters

    Indicates whether commercial strategy and sales force expansion are effectively driving growth for existing products.

    Based on the trends we're seeing today, we expect the second half of 2026 to be stronger than the first half of 2026, and we remain focused on accelerating revenue growth as we move through the balance of the year.

    Q&A highlights

    7

    How much momentum can ralinepag and SMI recapture given increased competition in the space?

    Ralinepag is seen as a multibillion-dollar opportunity due to its super prostacyclin data and once-daily oral differentiation. SMI is viewed as a differentiated delivery method for inhaled therapies with potential tolerability benefits, positioning the company well against competition.

    “I think with -- similarly with SMI, I think we look at SMI as really being a really differentiated way to deliver inhaled therapies across eventually all of our indications.”

    asked by Joseph Thome · answered by Michael Benkowitz

    2 min read4 chapters

    Detailed Narrative

    01

    Pipeline Advancements and Regulatory Submissions

    The first half of 2026 was pivotal, marked by exceptional clinical results from the ADVANCE OUTCOMES study for ralinepag in PAH and the unblinding of TETON 1 for nebulized Tyvaso in IPF, which surpassed TETON 2 results. These led to the submission of two significant new drug applications to the FDA: an sNDA for nebulized Tyvaso in IPF and an NDA for ralinepag in PAH. Additional filings, including an IND for ralinepag and an NDA for treprostinil SMI, are planned for later this year, with potential approvals for these three assets anticipated in 2027, representing multi-billion dollar opportunities.

    02

    Organ Pipeline Progress and Expansion

    United Therapeutics continues to make strong progress in its organ pipeline, aiming to expand the availability of transplantable organs. The UKidney EXPAND study is advancing well, with the initial 6-patient cohort expected to complete later this year. The company anticipates initiating the SIMO kidney extend registration-enabling study soon and is working to commence the Express Heart Study following FDA clearance. Furthermore, two additional commercial-scale DPF facilities in Minnesota and Texas are slated for completion by the end of the year, underscoring leadership in xenotransplantation.

    03

    Commercial Performance and Strategy

    Q2 FY26 total revenue of $783 million was flat quarter-over-quarter and below expectations, primarily due to competitive pressures on nebulized Tyvaso. However, Tyvaso DPI demonstrated growth and significant underlying momentum with record starts, referrals, total patients, and commercial patients. The company doubled its sales force, deploying new representatives in early July to enhance physician engagement across PAH and PH ILD, and expects improved performance in the second half of 2026. The commercial strategy focuses on leveraging differentiated therapies and preparing for future launches.

    04

    Capital Allocation and Strategic Acquisitions

    The company maintains a disciplined approach to capital allocation, positioning itself for high operating efficiency. Capital has been deployed towards internal growth objectives and returning capital to shareholders. A recent example is the acquisition of Thymmune Therapeutics, which adds a promising thymus-based regenerative medicine platform. This acquisition aligns with United Therapeutics' mission to restore immune function and broadens its organ alternative strategy, strengthening its long-term value creation potential.

    AI-generated summary of the company’s earnings call. Not investment advice.